FDAnews
www.fdanews.com/articles/96909-phosphagenics-announces-results-of-transdermal-insulin-trial

Phosphagenics Announces Results of Transdermal Insulin Trial

August 8, 2007

Australian company Phosphagenics announced that a Phase 1b clinical trial, conducted by the Clinical Medical Analytical Excellence (CMAX), an independent clinical research organization, assessed the efficacy and safety of two improved TPM/Insulin formulations in 45 volunteers.

The results for the lead formulation showed the blood endogenous insulin and C-peptide responses over time were statistically different in subjects who received the improved TPM/Insulin formulation when compared with subjects that received the placebo formulation, Phosphagenics said.

According to the company, blood glucose concentrations were lower in subjects treated with the improved TPM/Insulin formulation. The effect of the treatment lasted for up to eight hours after application of the gel, the company added. 

The company said it intends to continue clinical development of its transdermal insulin and that preparations are underway for a Phase II trial to be conducted by CMAX.